Answers are grounded in this paper and cite their sources.
Sir,The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. Therapeutic solutions are currently being tested for COVID-19, the SARS-CoV-2-associated pneumonia. Ritonavir-boosted lopinavir is included in the investi-gational therapies. A recent in vitro study reported that lopinavir inhibits SARS-CoV-2 replication with a 50% effective concentration (EC 50 ) of 16720ng/mL. 1 Here we describe lopinavir pharmacokinetics in COVID-19 patients treated with ritonavir-boosted lopinavir at the Nantes University Hospital, France.
No takes yet. Share an insight, caveat, or question.
Grégoire et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: